Theramex And Enzene Continue Alliance With Deal For RoActemra Rival
Companies Aim To Commercialize Tocilizumab In Europe, UK, Switzerland And Australia
Theramex and Enzene have struck a deal to commercialize a tocilizumab biosimilar rival to Roche’s RoActemra in Europe – including the UK and Switzerland – as well as Australia. The two companies recently partnered for Enzene’s proposed biosimilar version of Prolia (denosumab).
You may also be interested in...
Roche gave small insight into its expectations around biosimilar competition for its Actemra/RoActemra (tocilizumab) treatment for inflammatory diseases. Extraordinary demand for the biologic led sales to skyrocket by 143% in the third quarter and caused supply constraints for the originator.
ANI Pharmaceuticals has finally delivered its long-awaited launch of purified Cortrophin Gel (repository corticotropin injection) in the US, accompanying the launch with its ‘Cortrophin In Your Corner’ dedicated program to increase access and provide reimbursement support.
To extend its representation in Europe, IGBA has welcomed the generic and biosimilar drug association of Serbia and Montenegro – Genezis – to the global off-patent industry body.